Nasdaq

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation ...
Nasdaq

Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...
Monthly Prescribing Reference

Sacral Neuromodulation Device Approved for OAB, Urinary Retention

The Axonics r-SNM System includes a neurostimulator, patented tined lead, remote control, and a charging system. The small, neurostimulator is implanted through a minimally invasive outpatient ...
MD&M East

Axonics Closes a Portfolio Gap in Sacral Neuromodulation

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...